To assess the association between RB1 mutation or inactivation and the benefit of ICIs in SCLC, Dowlati et al. retrospectively collected data from 42 SCLC patients receiving either single-agent ICI or ICI combination therapy. The gene discussed is RB1; the disease is small cell lung carcinoma.